Here's Why Geron Corporation Fell as Much as 16.6% Today
Shares of clinical stage biopharma Geron Corporation (NASDAQ: GERN) fell nearly 17% Tuesday after management provided a clinical update on its only drug candidate, imetelstat, which is being investigated for treating myelofibrosis (MF) and myelodysplastic syndromes (MDS).
Development partner Janssen Oncology, which is a subsidiary of Johnson & Johnson, has decided to alter the ongoing IMerge phase 2/3 trial investigating MDS. Janssen Oncology also hasn't decided whether or not to commit to imetelstat for the IMbark phase 2 trial in MF.
As of 12:06 p.m. EDT, the stock had settled to a 12.3% loss.
Source: Fool.com
Geron Corp. Stock
€4.29
7.600%
Geron Corp. is currently one of the favorites of our community with 17 Buy predictions and no Sell predictions.
As a result the target price of 5 € shows a slightly positive potential of 16.6% compared to the current price of 4.29 € for Geron Corp..
